Biogen Inc. (BIIB) stock price, quote and key numbers
Updated 28 September 2026, 09:52 ET
Biogen Inc. (BIIB) closed at $227.60 on 25 September 2026, up 0.5%. That leaves it up 5.6% over a week, up 3.0% over a month and up 65.3% over a year. It is at the top of its 52 week range of $135.39 to $229.19. The median analyst price target of $241 sits 5.9% above the close.
The price
Changes compare dividend and split adjusted closes over trading sessions, so the one year figure is the last close against the close 252 sessions earlier. The 52 week range uses the daily highs and lows of the same window. Read the guide: How to read a stock quote.
The live price, the day's chart and the pre market and after hours prints are in the app: open BIIB in Just Stock Quotes.
Trend and range
BIIB trades above both its 50 day average of $212.96 and its 200 day average of $193.95, the shape of an uptrend. The 50 day average sits above the 200 day average. Its beta against the S&P 500 over the last year is 0.38, a stock that barely follows the market. It is 0.7% below its 52 week high and 68.1% above its 52 week low.
Moving averages smooth the closes of the last 50 and 200 sessions; being above or below them describes the trend, it does not predict it. Beta is how much the stock moved for each move in the S&P 500 over the year. Read the guide: Moving averages, the 52 week range and beta.
What analysts say
In the last 90 days 16 firms recorded 19 actions on BIIB: 17 kept a view and 2 upgrades. Price targets: 15 raised and 3 lowered. The most recent targets from 19 firms run from $175 to $300, with a median of $241, 5.9% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 10 Sep 2026 | HSBC | Maintains Reduce | $165.00 to $175.00 |
| 3 Sep 2026 | Piper Sandler | Reiterates Overweight | $225.00 to $245.00 |
| 25 Aug 2026 | RBC Capital | Maintains Outperform | $240.00 to $260.00 |
| 13 Aug 2026 | Wolfe Research | Upgrades to Outperform from Peer Perform | $300.00 |
| 4 Aug 2026 | Mizuho | Maintains Outperform | $221.00 to $241.00 |
| 3 Aug 2026 | Citigroup | Maintains Neutral | $200.00 to $215.00 |
A target is one firm's guess at the price a year out, and the average runs optimistic. The useful reading is the mood: high targets and a wall of buys mean high expectations. Read the guide: What analyst ratings and price targets tell you.
Earnings
The next report is on the calendar for 28 October 2026 for Q3 2026, with earnings per share expected at $2.04. The last report, on 29 July 2026 for Q2 2026, showed EPS of $3.60 against $2.35 expected, a beat of 53.2%, on revenue of $2.7 billion. Biogen Inc. beat the EPS estimate in 8 of its last 8 reported quarters.
Set a percent move alert before the report and the app pings you when the stock reacts, even after hours: open BIIB in Just Stock Quotes.
The numbers
Over the trailing twelve months Biogen Inc. shows revenue growth of 1.23%, a gross margin of 75.49%, an operating margin of 19.10% and a return on equity of 7.70%.
| Measure | Value | Percentile |
|---|---|---|
| Revenue growth, TTM | 1.2% | 36th |
| Net income growth, TTM | -7.2% | 38th |
| Gross margin | 75.5% | 87th |
| Operating margin | 19.1% | 79th |
| Free cash flow margin | 24.4% | 87th |
| Return on equity | 7.7% | 60th |
| Return on assets | 4.8% | 79th |
| Debt to equity | 0.34 | 56th |
| Current ratio | 3.06 | 79th |
| Effective tax rate | 15.5% | 58th |
The percentile ranks the company against every US company the data covers; a high percentile means most companies score lower.
Margins say how much of each dollar of sales becomes profit, returns say how hard the balance sheet works, and debt to equity says how much of it is borrowed. The valuation ratios, price to earnings and the rest, are in the app on the stock page. Read the guide: The valuation ratios on a stock page.
About Biogen Inc.
- Exchange
- Nasdaq
- Sector
- Health Care
- Industry
- Pharmaceutical Products
- Headquarters
- Weston, Massachusetts
- Chief executive
- Christopher A. Viehbacher
- Employees
- 8,720
- Website
- biogen.com
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. It also offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and pemphigus vulgaris.
In the same sector
Other Health Care names in the S&P 500, by market cap:
LLY Eli Lilly & Co.JNJ Johnson & JohnsonABBV AbbVie Inc.MRK Merck & Co. Inc.UNH UnitedHealth Group Inc.TMO Thermo Fisher Scientific Inc.AMGN Amgen Inc.GILD Gilead Sciences, Inc.
Learn
- How to read a stock quote
- Reading a price chart from one day to one year
- Moving averages, the 52 week range and beta
- What analyst ratings and price targets tell you
- The valuation ratios on a stock page
- Price alerts, targets and percent moves
Add BIIB to your watchlist, set a price alert, watch the live chart and ask FundSpec AI about it. No account, no subscription. The same screen is in the iPhone, iPad and Android apps.
Open BIIB in Just Stock Quotes